Persistence of anti-HBs among health care personnel immunized with hepatitis B vaccine.

Abstract

Health care personnel who received the hepatitis B vaccine (Heptavax-BR, MSD) were followed for persistence of hepatitis B surface antibody (anti-HBs). Response occurred in 135/146 (92.5 percent) vaccinees. Loss of anti-HBs (less than 72 RIA units; 10 S/N) occurred in 35.9 percent during the 36-month surveillance. Stepwise discriminant analysis found age and magnitude of initial antibody level, but not weight-height index, to be predictive of antibody loss over the 36 months. Twenty-four of 27 employees (88.9 percent) who lost anti-HBs responded to a fourth vaccine dose. In contrast, three of eight initial non-responders (37.5 percent) developed antibody after a fourth vaccine dose.

• Authors: M T Pasko, T R Beam Jr
• Journal: American journal of public health (Am J Public Health) Vol. 80 Issue 5 Pg. 590-3 (May 1990) ISSN: 0090-0036 [Print] United States
• PMID: 2139306 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Hepatitis B Antibodies
• Hepatitis B Vaccines
• Viral Hepatitis Vaccines

Topics

• Adult
• Age Factors
• Discriminant Analysis
• Female
• Health Workforce
• Hepatitis B (immunology, prevention & control)
• Hepatitis B Antibodies (blood)
• Hepatitis B Vaccines
• Humans
• Immunization, Secondary
• Male
• Radioimmunoassay
• Vaccination
• Viral Hepatitis Vaccines